2021 Conference Publication Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive after Treatment for Relapsed Follicular Lymphoma: Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 StudyTrotman, Judith, Presgrave, Peter, Carradice, Duncan P., Lenton, Douglas Stuart, Gandhi, Maher, Cochrane, Tara, Badoux, Xavier, NKhoma, Gloria, Butcher, Belinda, Fulham, Michael and Johnston, Anna (2021). Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive after Treatment for Relapsed Follicular Lymphoma: Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study. 63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta Ga, Dec 11-14, 2021. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2021-146343 |
2021 Journal Article Event-Free and Overall Survival in over 6,000 Patients Treated with Frontline Immunochemotherapy for Follicular Lymphoma between 2002-2018: First Report from the International FLIPI24 ConsortiumMaurer, Matthew J., Prochazka, Vit K, Flowers, Christopher R., Jakobsen, Lasse H., Villa, Diego, Weibull, Caroline, Cahn, Elliot J., Ghesquieres, Herve, Kridel, Robert, Gandhi, Maher, Cheah, Chan Yoon, Hawkes, Eliza, Seymour, John F., Freeman, Ciara L., Clausen, Michael Roost, Wahlin, Björn, Link, Brian K., Smedby, Karin Ekstroem, Sehn, Laurie H., Trněný, Marek, El-Galaly, Tarec Christoffer and Cerhan, James R. (2021). Event-Free and Overall Survival in over 6,000 Patients Treated with Frontline Immunochemotherapy for Follicular Lymphoma between 2002-2018: First Report from the International FLIPI24 Consortium. Blood, 138 (Supplement 1), 138. doi: 10.1182/blood-2021-145883 |
2021 Journal Article Immunity reloaded: deconstruction of the PD-1 axis in B cell lymphomasBednarska, Karolina, Nath, Karthik, Nicol, William and Gandhi, Maher K. (2021). Immunity reloaded: deconstruction of the PD-1 axis in B cell lymphomas. Blood Reviews, 50 100832, 100832. doi: 10.1016/j.blre.2021.100832 |
2021 Journal Article Intratumoral T‐cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B‐cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimmunotherapyShanavas, Mohamed, Law, Soi‐Cheng, Hertzberg, Mark, Hicks, Rodney J., Seymour, John F., Li, Zhixiu, Merida de Long, Lilia, Nath, Karthik, Sabdia, Muhammed B., Gunawardana, Jay, Gandhi, Maher K. and Keane, Colm (2021). Intratumoral T‐cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B‐cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimmunotherapy. Clinical and Translational Immunology, 10 (11) e1351, e1351. doi: 10.1002/cti2.1351 |
2021 Journal Article Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic targetGould, Clare, Lickiss, Jennifer, Kankanige, Yamuna, Yerneni, Satwica, Lade, Stephen, Gandhi, Maher K., Chin, Collin, Yannakou, Costas K., Villa, Diego, Slack, Graham W., Markham, John F., Tam, Constantine S., Nelson, Niles, Seymour, John F., Dickinson, Michael, Neeson, Paul J., Westerman, David and Blombery, Piers (2021). Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target. British Journal of Haematology, 195 (1) bjh.17789, 113-118. doi: 10.1111/bjh.17789 |
2021 Journal Article Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphomaNath, Karthik, Law, Soi-Cheng, Sabdia, Muhammed B., Gunawardana, Jay, de Long, Lilia M., Sester, David, Shanavas, Mohamed, Tsang, Hennes, Tobin, Joshua W. D., Halliday, Sarah-Jane, Hernandez, Annette, Cross, Donna, Bird, Robert J., Jain, Sanjiv, Keane, Colm, Talaulikar, Dipti, Trotman, Judith, Law, Phillip and Gandhi, Maher K. (2021). Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma. Blood Advances, 5 (12), 2644-2649. doi: 10.1182/bloodadvances.2020004051 |
2021 Journal Article Successful treatment of Epstein–Barr virus–associated primary central nervous system lymphoma due to post‐transplantation lymphoproliferative disorder, with ibrutinib and third‐party Epstein–Barr virus–specific T cellsLaw, Soi C., Hoang, Thanh, O'Rourke, Kacey, Tobin, Joshua W. D., Gunawardana, Jay, Loo‐Oey, Dorothy, Bednarska, Karolina, Merida de Long, Lilia, Sabdia, Muhammed B., Hapgood, Greg, Blyth, Emily, Clancy, Leighton, Hennig, Stefanie, Keane, Colm and Gandhi, Maher K. (2021). Successful treatment of Epstein–Barr virus–associated primary central nervous system lymphoma due to post‐transplantation lymphoproliferative disorder, with ibrutinib and third‐party Epstein–Barr virus–specific T cells. American Journal of Transplantation, 21 (10) ajt.16628, 3465-3471. doi: 10.1111/ajt.16628 |
2021 Journal Article Discordant solutions to discordant problemsTobin, Joshua W. D. and Gandhi, Maher K. (2021). Discordant solutions to discordant problems. Blood, 137 (21), 2857-2858. doi: 10.1182/blood.2021011362 |
2021 Other Outputs A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphomaTobin, Joshua W.D., Crothers, Anna, Eric, Ti, Mollee, Peter, Gandhi, Maher K., Scuffham, Paul and Hapgood, Greg (2021). A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphoma. doi: 10.1101/2021.03.24.21254220 |
2021 Journal Article EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entityGandhi, Maher K., Hoang, Thanh, Law, Soi C., Brosda, Sandra, O'Rourke, Kacey, Tobin, Joshua W. D., Vari, Frank, Murigneux, Valentine, Fink, J. Lynn, Gunawardana, Jay, Gould, Clare M., Oey, Harald, Bednarska, Karolina, Delecluse, Susanne, Trappe, Ralf Ulrich, de Long, Lilia Merida, Sabdia, Muhammed Bilal, Bhagat, Govind, Hapgood, Greg, Blyth, Emily, Clancy, Leighton E., Wight, Joel, Hawkes, Eliza A., Rimsza, Lisa M., Maguire, Alanna, Bojarczuk, Kamil, Chapuy, Bjoern and Keane, Colm (2021). EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. Blood, 137 (11), 1468-1477. doi: 10.1182/blood.2020008520 |
2021 Journal Article Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experienceLewis, Katharine L., Chin, Collin K., Manos, Kate, Casey, John, Hamad, Nada, Crawford, Julie, Ho, Shir-Jing, Issa, Samar, Grigg, Andrew, Wood, Peter, Gandhi, Maher K., Do, Bryan, Nastoupil, Loretta, Hawkes, Eliza A. and Cheah, Chan Y. (2021). Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience. British Journal of Haematology, 192 (6) bjh.16946, 1049-1053. doi: 10.1111/bjh.16946 |
2021 Journal Article Targeted treatment of follicular lymphomaNath, Karthik and Gandhi, Maher K. (2021). Targeted treatment of follicular lymphoma. Journal of Personalized Medicine, 11 (2) 152, 1-22. doi: 10.3390/jpm11020152 |
2021 Journal Article A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphomaTobin, Joshua W. D., Crothers, Anna, Ma, Ti Eric, Mollee, Peter, Gandhi, Maher K., Scuffham, Paul and Hapgood, Greg (2021). A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma. Leukemia and Lymphoma, 62 (14), 1-9. doi: 10.1080/10428194.2021.1957866 |
2021 Journal Article Tumor microenvironment of follicular lymphomaNath, Karthik, Tsang, Hennes and Gandhi, Maher K. (2021). Tumor microenvironment of follicular lymphoma. Annals of Lymphoma, 5, 1-19. doi: 10.21037/aol-20-55 |
2021 Book Chapter Host genetic mutations and expression analyses in PTLDLees, Charlotte and Gandhi, Maher K. (2021). Host genetic mutations and expression analyses in PTLD. Post-transplant lymphoproliferative disorders. (pp. 39-50) edited by Vikas R. Dharnidharka, Michael Green, Steven A. Webber and Ralf Ulrich Trappe. Cham, Switzerland: Springer . doi: 10.1007/978-3-030-65403-0_4 |
2020 Journal Article Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environmentKobayashi, Takumi, Lam, Pui Yeng, Jiang, Hui, Bednarska, Karolina, Gloury, Renee Elyse, Murigneux, Valentine, Tay, Joshua, Jacquelot, Nicolas, Li, Rui, Tuong, Zewen Kelvin, Leggatt, Graham, Gandhi, Maher K., Hill, Michelle M, Belz, Gabrielle T., Ngo, Shyuan, Kallies, Axel and Mattarollo, Stephen R. (2020). Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment. Blood, 136 (26), 3004-3017. doi: 10.1182/blood.2020005602 |
2020 Conference Publication A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphomaTobin, Joshua W.D., Hapgood, Greg, Gandhi, Maher K., Mollee, Peter, Ma, Ti, Crothers, Anna and Scuffham, Paul (2020). A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphoma. 62nd ASH Annual Meeting and Exposition, Online, 5-8 December 2020. Washington, DC USA: American Society of Hematology. doi: 10.1182/blood-2020-138590 |
2020 Conference Publication Neoantigens are typically associated with intact HLA class I presentation in early-stage follicular lymphomaTsang, Hennes, Patch, Ann-Marie, Keane, Colm, Law, Soi C., Gunawardana, Jay, Blombery, Piers, Thompson, Ella R., Sabdia, Muhammed B., De Long, Lilia Merida, Belle, Clemence J., Nath, Karthik, Tobin, Joshua W.D., Kazakoff, Stephen H., Seymour, John F., MacManus, Michael and Gandhi, Maher K. (2020). Neoantigens are typically associated with intact HLA class I presentation in early-stage follicular lymphoma. 62nd ASH Annual Meeting and Exposition, Online, 5-8 December 2020. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2020-135954 |
2020 Journal Article DA-EPOCH-R in Burkitt Lymphoma: Is it enough for high-risk disease?Hertzberg, Mark, Joske, David J. L. and Gandhi, Maher K. (2020). DA-EPOCH-R in Burkitt Lymphoma: Is it enough for high-risk disease?. Journal of Clinical Oncology, 38 (31), 3722-3723. doi: 10.1200/jco.20.01850 |
2020 Journal Article Genetic aberrations of NLRC5 are associated with downregulated MHC‐I antigen presentation and impaired T‐cell immunity in follicular lymphomaGunawardana, Jay, Lee, Justina N., Bednarska, Karolina, Murigneux, Valentine, Long, Lilia Merida, Sabdia, Muhammed B., Birch, Simone, Tobin, Joshua W. D. and Gandhi, Maher K. (2020). Genetic aberrations of NLRC5 are associated with downregulated MHC‐I antigen presentation and impaired T‐cell immunity in follicular lymphoma. eJHaem, 1 (2) jha2.116, 517-526. doi: 10.1002/jha2.116 |